血常规对乳腺癌的预后评估价值的研究进展  

Research progress on the value of blood routine in the prognostic evaluation of breast cancer

作　　者：杨宇 郭佳妮[1] 黄明德[1] YANG Yu;GUO Jiani;HUANG Mingde(Department of Medical Oncology,the Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University,Jiangsu Province,Huaian223300,China)

机构地区：[1]南京医科大学附属淮安第一医院肿瘤内科,江苏淮安223300

出　　处：《中国医药导报》2022年第4期45-48,56,共5页China Medical Herald

基　　金：江苏省卫生健康委员会高层次卫生人才“六个一工程”拔尖人才项目(LGY2019046)。

摘　　要：乳腺癌已成为女性最常见的恶性肿瘤,严重威胁女性身心健康。最近越来越多的研究已经证实血常规中中性粒细胞、血小板、淋巴细胞等单独指标及中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、淋巴细胞与单核细胞比值等血常规复合指标与乳腺癌治疗效果及预后有关。血常规指标具有简单、经济、无创等优点,然而也存在标准缺乏统一、样本量小、机制尚不明确等不足。本文针对血常规对乳腺癌预后的评估价值的研究进展进行综述。Breast cancer has become the most common malignant tumor in women,which seriously threatens women’s physical and mental health.Recently,more and more studies have confirmed that the indicators such as neutrophils,platelets,lymphocytes,and the combined indicators such as the ratio of neutrophils to lymphocytes,the ratio of platelets to lymphocytes,and the ratio of lymphocytes to monocytes in blood routine are related to the therapeutic effect and prognosis of breast cancer.Blood routine indicators have the advantages of simplicity,economy and non-invasive,but there are also deficiencies such as lack of unified standards,small sample size,and unclear mechanism.This article reviews the research progress of the value of blood routine in the evaluation of prognosis of breast cancer.

关 键 词：乳腺癌 血常规 淋巴细胞 预后 

分 类 号：R737.9[医药卫生—肿瘤]